[Evaluation of therapeutic effects of strontium-89 on osseous metastases of prostate cancer by bone scanning and B-AKP measurement].
OBJECTIVE
To evaluate the therapeutic effects of strontium-89 on osseous metastases of prostate cancer by bone scanning and bone alkaline phosphatase (B-AKP) measurement.


METHODS
One week before and within 6 months after strontium-89 therapy, bone scanning and B-AKP measurement were performed in 73 patients with bone metastases of prostate cancer. 1. According to the number of osseous lesions on bone imaging, the patients were divided into Grade 0, 1, 2 and 3, and the numbers of bone lesions before and after therapy were compared by t-test. 2. Tumor to non-tumor ratios(T/NT) before and after treatment were calculated and compared. 3. Changes in B-AKP before and after therapy were compared.


RESULTS
1. Among the 73 patients, bone scanning revealed 618 bone lesions, averaging 8.6 +/- 7.4 before treatment. The number decreased to 349, averaging 3.8 +/- 6.7 after treatment, which showed a significant reduction (t = 4.079, P < 0.01). 2. After therapy, T/NT of bone lesions decreased significantly (t = 7.907, P < 0.01) from 5.36 +/- 4.67 to 3.17 +/- 2.95. 3. B-AKP decreased significantly (t = 3.349, P < 0.002) from (28.4 +/- 14.8) microgram/L to (20.9 +/- 11.7) microgram/L. 4. By bone scanning combined with B-AKP measurement, 5 false positive cases and 6 false negative cases were corrected.


CONCLUSIONS
There is certain complementarity between bone scanning and B-AKP measurement, and they should be used in a combined way to achieve accurate evaluation of the therapeutic effects of strontium-89.
Fan
Yixiang
Y
Department of Oncology, Nanfang Hospital, First Military Medical University, Guangzhou, Guangdong 510515, China. fanyixiang@163.com
Luo
Rongcheng
R
Li
Guiping
G
Huang
Kai
K
D000368:Aged; D000469:Alkaline Phosphatase / Q000032:analysis*; D001859:Bone Neoplasms / Q000201:enzymology / Q000532:radiotherapy* / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging* / Q000201:enzymology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011877:Radionuclide Imaging; D013324:Strontium / Q000627:therapeutic use*
D000469:Alkaline Phosphatase; D017430:Prostate-Specific Antigen; C025700:strontium chloride; D013324:Strontium